Literature DB >> 26944711

Universal varicella vaccine immunization in Japan.

Tetsushi Yoshikawa1, Yoshiki Kawamura2, Masahiro Ohashi2.   

Abstract

In 1974, Japanese scientists developed a live attenuated varicella vaccine based on the Oka strain. The efficacy of the vaccine for the prevention of varicella has been primarily demonstrated in studies conducted in the United States following the adoption of universal immunization using the Oka strain varicella vaccine in 1996. Although the vaccine was developed by Japanese scientists, until recently, the vaccine has been administered on a voluntary basis in Japan resulting in a vaccine coverage rate of approximately 40%. Therefore, Japan initiated universal immunization using the Oka strain varicella vaccine in November 2014. Given the transition from voluntary to universal immunization in Japan, it will also be important to monitor the epidemiology of varicella and herpes zoster. The efficacy and safety of co-administration of the varicella vaccine and measles, mumps, and rubella vaccine have been demonstrated in many countries; however, there was no data from Japan. In order to adopt the practice of universal immunization using the Oka strain varicella vaccine in Japan, data demonstrating the efficacy and safety of co-administration of varicella vaccine and measles and rubella (MR) vaccine were required. Additionally, we needed to elucidate the appropriate time interval between the first and second administrations of the vaccine. It is also important to differentiate between wild type and Oka vaccine type strains in herpes zoster patient with past history of varicella vaccine. Thus, there are many factors to consider regarding the adoption of universal immunization in Japan to control varicella zoster virus (VZV) infections.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26944711     DOI: 10.1016/j.vaccine.2016.02.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Approved Antiviral Drugs over the Past 50 Years.

Authors:  Erik De Clercq; Guangdi Li
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

2.  A Live Olfactory Mouse Cytomegalovirus Vaccine, Attenuated for Systemic Spread, Protects against Superinfection.

Authors:  Helen E Farrell; Kimberley Bruce; Philip G Stevenson
Journal:  J Virol       Date:  2021-08-25       Impact factor: 5.103

Review 3.  Varicella and herpes zoster vaccine development: lessons learned.

Authors:  Charlotte Warren-Gash; Harriet Forbes; Judith Breuer
Journal:  Expert Rev Vaccines       Date:  2017-10-30       Impact factor: 5.217

4.  Severe Herpes Zoster Following Varicella Vaccination in Immunocompetent Young Children.

Authors:  Amaran Moodley; Jack Swanson; Charles Grose; Daniel J Bonthius
Journal:  J Child Neurol       Date:  2019-01-10       Impact factor: 1.987

5.  Changes in awareness and knowledge concerning mother-to-child infections among Japanese pregnant women between 2012 and 2018.

Authors:  Shutaro Suga; Kazumichi Fujioka; Ruka Nakasone; Shinya Abe; Sachiyo Fukushima; Mariko Ashina; Kosuke Nishida; Kandai Nozu; Kazumoto Iijima; Kenji Tanimura; Hideto Yamada
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240

6.  Economic Evaluation of Universal Varicella Vaccination in Mexico.

Authors:  Enrique Chacon-Cruz; Estelle Meroc; Sue Ann Costa-Clemens; Ralf Clemens; Thomas Verstraeten
Journal:  Pediatr Infect Dis J       Date:  2022-05-01       Impact factor: 3.806

7.  Reconstructing the transmission dynamics of varicella in Japan: an elevation of age at infection.

Authors:  Ayako Suzuki; Hiroshi Nishiura
Journal:  PeerJ       Date:  2022-01-19       Impact factor: 2.984

8.  No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination.

Authors:  Stephane Carryn; Brigitte Cheuvart; Michael Povey; Alemnew F Dagnew; Rafael Harpaz; Robbert van der Most; Giacomo Casabona
Journal:  J Infect Dis       Date:  2022-02-01       Impact factor: 7.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.